Table 72Summary of combination therapy study and patient characteristics: case series studies

Study designIntervention PeriodInterventionAge, Mean or Median (Range)ECOG ScoreCP
A%; B%; C%
A%; B%
Previous LDT %
Gao et al. 201194
Retrospective case series11/2001 - 09/2009TACE with lipiodol, perarubicin (50 mg/m2), DDP (80 mg/m2) via hepatic artery 1–2 times followed by CT-guided percutaneous ethanol ablation with ethanol (99% concentration) mixed with lipiodol (9:1 volume ratio, mean 30.5 mL per patient) via hepatic arteryMean: 57.2 (NR)NRA: 60.3;
B: 39.7;
C: 0
Lencioni et al. 200891
Prospective case series09/2005 - 11/2006Percutaneous, US-guided RFA (target temp 105°C) followed within 24 hours with DEB of doxorubicin (range 50–125 mg; mean 60.2 mg; SD 21.8 mg) via arterial branches feeding the tumorMean: 70 (63–83)NRNRNRNR
Liao et al. 200895
Prospective case series01/2000 - 12/2005TAE with lipiodol followed by RFA between the 7th and 14th days after TAEMean: 56.4 (43–81)NRA: 75;
B: 25
C: 0
NRTAE and/or PEI: 17.1
Zhao et al. 201233
Retrospective case series01/2000 – 12/2009TACE with lipiodol (10–30 ml), epirubicin (6–12 mg), mitomycin C (6–12 mg) and normal saline solution (3 ml) via femoral artery using the Seldinger technique followed by RFA 3–4 weeks later with multitined expandable electrodes (01/00-12/03) or monopolar electrode system (01/04-12/09)Mean: 53 (18–86)NRA: 79;
B: 21;
C: 0

Patient characteristics are reported for combined intermediate and advanced stage groups (n=122). Results are reported for the intermediate stage group separately (n=72).

Abbreviations: BCLC = Barcelona Clinic Liver Center hepatocellular carcinoma stage; CT = computed tomography; CP = Child-Pugh liver cirrhosis class; DEB = drug-eluting bead; ECOG = Eastern Cooperative Oncology Group; LDT = liver-directed therapy; N = number of patients; NR = not reported; RFA = radiofrequency ablation; SD = standard deviation; TACE = transarterial chemoembolization; TAE = transarterial embolization; US = ultrasound.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.